Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

(2013) Jack Cuzick et al.   LANCET

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

(2012) Erika A. Waters et al.   BREAST CANCER RESEARCH AND TREATMENT

Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials

(2012) R. S. Cecchini et al.   Cancer Prevention Research

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial

(2012) Angela M Cheung et al.   LANCET ONCOLOGY

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)

(2011) Carolyn D. Runowicz et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid

(2011) Angela Fagerlin et al.   BREAST CANCER RESEARCH AND TREATMENT

Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial

(2011) S. R. Land et al.   Cancer Prevention Research

Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review

(2011) Javaid Iqbal et al.   CANCER TREATMENT REVIEWS

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials

(2011) M. P. Goetz et al.   CLINICAL CANCER RESEARCH

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

(2011) Andrew N. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Helping Patients Decide: Ten Steps to Better Risk Communication

(2011) A. Fagerlin et al.   JNCI-Journal of the National Cancer Institute

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

(2011) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Lack, Need, and Opportunities for Decision-Making and Informational Tools to Educate Primary-Care Physicians and Women about Breast Cancer Chemoprevention

(2010) P. M. Ravdin   Cancer Prevention Research

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

(2010) V. G. Vogel et al.   Cancer Prevention Research

Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis

(2010) Kristine Ensrud et al.   CIRCULATION

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

(2010) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis

(2010) Mary E. Ropka et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women

(2010) A. Z. LaCroix et al.   JNCI-Journal of the National Cancer Institute

Lasofoxifene in Postmenopausal Women with Osteoporosis

(2010) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration

(2009) Victor G. Vogel et al.   Clinical Breast Cancer

Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene

(2009) Claudine Legault et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

(2009) Kala Visvanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Testing whether decision aids introduce cognitive biases: Results of a randomized trial

(2009) Peter A. Ubel et al.   PATIENT EDUCATION AND COUNSELING

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

(2008) Alan L. Burshell et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

(2008) Vered Stearns et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk

(2008) D. Grady et al.   JNCI-Journal of the National Cancer Institute

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer

(2008) Y. Shen et al.   JNCI-Journal of the National Cancer Institute

Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk

(2008) M. H. Gail   JNCI-Journal of the National Cancer Institute

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)

(2008) Valerie A Jenkins et al.   LANCET ONCOLOGY

Communicating side effect risks in a tamoxifen prophylaxis decision aid: The debiasing influence of pictographs

(2008) Brian J. Zikmund-Fisher et al.   PATIENT EDUCATION AND COUNSELING